The Biostatistics Resource Group (BRG) provides biostatistical collaboration, consultation, and quantitative research resources to clinical, laboratory, and prevention scientists at MD Anderson who are engaged in the planning, analysis, quality assurance, and interpretation of research studies. The BRG has pioneered the use of the Bayesian approach in adaptive clinical trials, particularly, in the Phase I and Phase II settings. The consultation and collaboration services of the BRG (in hours) have grown by 10% over the past 5 years. The primary equipment and technology of the BRG is a well-supported computing environment that extends across varied operating systems: Windows, Unix/Linux, and Mac OS X;providing access to more than SO non-standard desktop, client, and server applications;more than 300 terabytes of in-house storage space for home directories, research data, and data mirrors;and to in-house parallel computing capability through a 48-processor Cray XD1 HPC cluster and a 290-processor distributed computing Condor pool composed of over 160 Windows workstations (with at least 2GB of memory) and 8 servers (ranging from 4GB to 16GB of memory). BRG services have been used by 1070 researchers over the past five years, with 79% of the use by peer-reviewed cancer center members. The BRG is requesting funding from the CCSG in the amount of 9% of the total operating budget. Publications cited using the BRG have appeared in several high impact journals such as JAMA, J Clin Oncol and J Natl Cancer Inst. Annually, MD Anderson has provided institutional support to the BRG in the amount of $3,952,162. The BRG will continue to attract highly-qualified biostatistics faculty and to encourage their participation in multidisciplinary collaborative research;to hire and train highly-qualified statistical analysts and to encourage their professional growth through advanced education in statistics methodology and the application of computational tools;to instruct and mentor talented graduate and postdoctoral researchers;and to design innovative biostatistical approaches that promote discovery in cancer research. The BRG will continue to be the world's leading group in the development and application of Bayesian methodology for medical research.

Public Health Relevance

The BRG provides statistical collaboration and consultation services in support of cancer research in laboratory experiments and clinical trials, plays a direct role in the planning and review of clinical protocols, provides educational programs in biostatistical methods, and designs, develops, distributes, and implements software and database systems to support various computational needs of cancer researchers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-39
Application #
8759801
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
39
Fiscal Year
2014
Total Cost
$849,328
Indirect Cost
$318,721
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Mehrvarz Sarshekeh, Amir; Xiong, Henry Q; Iizuka, Kenzo et al. (2018) Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer. Invest New Drugs 36:895-902
Lang, Frederick F; Conrad, Charles; Gomez-Manzano, Candelaria et al. (2018) Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. J Clin Oncol 36:1419-1427
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Talluri, Rajesh; Shete, Sanjay (2018) An approach to estimate bidirectional mediation effects with application to body mass index and fasting glucose. Ann Hum Genet 82:396-406
Bhadra, Anindya; Rao, Arvind; Baladandayuthapani, Veerabhadran (2018) Inferring network structure in non-normal and mixed discrete-continuous genomic data. Biometrics 74:185-195
Basourakos, Spyridon P; Davis, John W; Chapin, Brian F et al. (2018) Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int 121:69-76
Naqvi, Kiran; Jabbour, Elias; Skinner, Jeffrey et al. (2018) Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 124:2740-2747
Economides, Minas P; Amit, Moran; Mahale, Parag S et al. (2018) Impact of chronic hepatitis C virus infection on the survival of patients with oropharyngeal cancer. Cancer 124:960-965
Hurvitz, Sara A; Martin, Miguel; Symmans, W Fraser et al. (2018) Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 19:115-126
Zhu, Hongxiao; Versace, Francesco; Cinciripini, Paul M et al. (2018) Robust and Gaussian spatial functional regression models for analysis of event-related potentials. Neuroimage 181:501-512

Showing the most recent 10 out of 12418 publications